Evaluation for new Phosphate Iron-based binder , Sucroferric Oxyhydroxide in Dialysis patient for E.B.M

Trial Profile

Evaluation for new Phosphate Iron-based binder , Sucroferric Oxyhydroxide in Dialysis patient for E.B.M

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Aug 2016

At a glance

  • Drugs Sucroferric oxyhydroxide (Primary) ; Lanthanum carbonate
  • Indications Hyperphosphataemia
  • Focus Therapeutic Use
  • Acronyms EPISODE
  • Most Recent Events

    • 20 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top